- call +1-201-465-4211
- email sales@mrinsights.biz
Interferon a (human leukocyte protein moiety reduced). A type I interferon consisting of 165 amino acid residues with lysine in position 23. This protein is produced by recombinant DNA technology and resembles interferon secreted by leukocytes. It is used extensively as an antiviral or antineoplastic agent. An oral form is being developed by Amarillo Biosciences.
Scope of the Report:
The global average price of Interferon Alpha-2a Biosimilar is in the decreasing trend, from 186.78 USD/Unit in 2013 to 64.67 USD/Unit in 2017. With the situation of global economy, prices will be in decreasing trend in the following five years.
The classification of Interferon Alpha-2a Biosimilar includes ordinary type and long-lasting type, and the proportion of ordinary type in 2017 is about 64%, and the proportion is in increasing trend from 2013 to 2017.
Interferon Alpha-2a Biosimilar is widely used for hepatitis C, hepatitis B and other diseases. The most proportion of Interferon Alpha-2a Biosimilar is used for hepatitis C, and the proportion in 2017 is 46%.
Europe is the largest supplier of Interferon Alpha-2a Biosimilar, with a production market share nearly 70% in 2017.
South America is the largest consumption place, with a consumption market share nearly 26% in 2017. Following South America, Europe is the second largest consumption place with the consumption market share of 22%.
Market competition is not intense. Roche, Biosidus, Zydus Cadila, Nanogen, Amega Biotech, Rhein Minapharm Biogenetics, PROBIOMED, 3sbio, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers; have been formed in the monopoly position in the industry.
The worldwide market for Interferon Alpha-2a Biosimilar is expected to grow at a CAGR of roughly -11.2% over the next five years, will reach 190 million US$ in 2024, from 390 million US$ in 2019, according to a new study.
This report focuses on the Interferon Alpha-2a Biosimilar in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers
Roche
Biosidus
Zydus Cadila
Nanogen
Amega Biotech
Rhein Minapharm Biogenetics
PROBIOMED
3sbio
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Long-lasting Type
Ordinary Type
Market Segment by Applications, can be divided into
Hepatitis C
Hepatitis B
Other
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Interferon Alpha-2a Biosimilar product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Interferon Alpha-2a Biosimilar, with price, sales, revenue and global market share of Interferon Alpha-2a Biosimilar in 2017 and 2018.
Chapter 3, the Interferon Alpha-2a Biosimilar competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Interferon Alpha-2a Biosimilar breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.
Chapter 12, Interferon Alpha-2a Biosimilar market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.
Chapter 13, 14 and 15, to describe Interferon Alpha-2a Biosimilar sales channel, distributors, customers, research findings and conclusion, appendix and data source.
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Market Overview
1.1 Interferon Alpha-2a Biosimilar Introduction
1.2 Market Analysis by Type
1.2.1 Long-lasting Type
1.2.2 Ordinary Type
1.3 Market Analysis by Applications
1.3.1 Hepatitis C
1.3.2 Hepatitis B
1.3.3 Other
1.4 Market Analysis by Regions
1.4.1 North America (United States, Canada and Mexico)
1.4.1.1 United States Market States and Outlook (2014-2024)
1.4.1.2 Canada Market States and Outlook (2014-2024)
1.4.1.3 Mexico Market States and Outlook (2014-2024)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany Market States and Outlook (2014-2024)
1.4.2.2 France Market States and Outlook (2014-2024)
1.4.2.3 UK Market States and Outlook (2014-2024)
1.4.2.4 Russia Market States and Outlook (2014-2024)
1.4.2.5 Italy Market States and Outlook (2014-2024)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China Market States and Outlook (2014-2024)
1.4.3.2 Japan Market States and Outlook (2014-2024)
1.4.3.3 Korea Market States and Outlook (2014-2024)
1.4.3.4 India Market States and Outlook (2014-2024)
1.4.3.5 Southeast Asia Market States and Outlook (2014-2024)
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil Market States and Outlook (2014-2024)
1.4.4.2 Egypt Market States and Outlook (2014-2024)
1.4.4.3 Saudi Arabia Market States and Outlook (2014-2024)
1.4.4.4 South Africa Market States and Outlook (2014-2024)
1.4.4.5 Turkey Market States and Outlook (2014-2024)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Roche
2.1.1 Business Overview
2.1.2 Interferon Alpha-2a Biosimilar Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Roche Interferon Alpha-2a Biosimilar Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
2.2 Biosidus
2.2.1 Business Overview
2.2.2 Interferon Alpha-2a Biosimilar Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Biosidus Interferon Alpha-2a Biosimilar Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
2.3 Zydus Cadila
2.3.1 Business Overview
2.3.2 Interferon Alpha-2a Biosimilar Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Zydus Cadila Interferon Alpha-2a Biosimilar Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
2.4 Nanogen
2.4.1 Business Overview
2.4.2 Interferon Alpha-2a Biosimilar Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Nanogen Interferon Alpha-2a Biosimilar Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
2.5 Amega Biotech
2.5.1 Business Overview
2.5.2 Interferon Alpha-2a Biosimilar Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Amega Biotech Interferon Alpha-2a Biosimilar Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
2.6 Rhein Minapharm Biogenetics
2.6.1 Business Overview
2.6.2 Interferon Alpha-2a Biosimilar Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Rhein Minapharm Biogenetics Interferon Alpha-2a Biosimilar Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
2.7 PROBIOMED
2.7.1 Business Overview
2.7.2 Interferon Alpha-2a Biosimilar Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 PROBIOMED Interferon Alpha-2a Biosimilar Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
2.8 3sbio
2.8.1 Business Overview
2.8.2 Interferon Alpha-2a Biosimilar Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 3sbio Interferon Alpha-2a Biosimilar Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
3 Global Interferon Alpha-2a Biosimilar Sales, Revenue, Market Share and Competition by Manufacturer (2017-2018)
3.1 Global Interferon Alpha-2a Biosimilar Sales and Market Share by Manufacturer (2017-2018)
3.2 Global Interferon Alpha-2a Biosimilar Revenue and Market Share by Manufacturer (2017-2018)
3.3 Market Concentration Rate
3.3.1 Top 3 Interferon Alpha-2a Biosimilar Manufacturer Market Share in 2018
3.3.2 Top 6 Interferon Alpha-2a Biosimilar Manufacturer Market Share in 2018
3.4 Market Competition Trend
4 Global Interferon Alpha-2a Biosimilar Market Analysis by Regions
4.1 Global Interferon Alpha-2a Biosimilar Sales, Revenue and Market Share by Regions
4.1.1 Global Interferon Alpha-2a Biosimilar Sales and Market Share by Regions (2014-2019)
4.1.2 Global Interferon Alpha-2a Biosimilar Revenue and Market Share by Regions (2014-2019)
4.2 North America Interferon Alpha-2a Biosimilar Sales and Growth Rate (2014-2019)
4.3 Europe Interferon Alpha-2a Biosimilar Sales and Growth Rate (2014-2019)
4.4 Asia-Pacific Interferon Alpha-2a Biosimilar Sales and Growth Rate (2014-2019)
4.5 South America Interferon Alpha-2a Biosimilar Sales and Growth Rate (2014-2019)
4.6 Middle East and Africa Interferon Alpha-2a Biosimilar Sales and Growth Rate (2014-2019)
5 North America Interferon Alpha-2a Biosimilar by Country
5.1 North America Interferon Alpha-2a Biosimilar Sales, Revenue and Market Share by Country
5.1.1 North America Interferon Alpha-2a Biosimilar Sales and Market Share by Country (2014-2019)
5.1.2 North America Interferon Alpha-2a Biosimilar Revenue and Market Share by Country (2014-2019)
5.2 United States Interferon Alpha-2a Biosimilar Sales and Growth Rate (2014-2019)
5.3 Canada Interferon Alpha-2a Biosimilar Sales and Growth Rate (2014-2019)
5.4 Mexico Interferon Alpha-2a Biosimilar Sales and Growth Rate (2014-2019)
6 Europe Interferon Alpha-2a Biosimilar by Country
6.1 Europe Interferon Alpha-2a Biosimilar Sales, Revenue and Market Share by Country
6.1.1 Europe Interferon Alpha-2a Biosimilar Sales and Market Share by Country (2014-2019)
6.1.2 Europe Interferon Alpha-2a Biosimilar Revenue and Market Share by Country (2014-2019)
6.2 Germany Interferon Alpha-2a Biosimilar Sales and Growth Rate (2014-2019)
6.3 UK Interferon Alpha-2a Biosimilar Sales and Growth Rate (2014-2019)
6.4 France Interferon Alpha-2a Biosimilar Sales and Growth Rate (2014-2019)
6.5 Russia Interferon Alpha-2a Biosimilar Sales and Growth Rate (2014-2019)
6.6 Italy Interferon Alpha-2a Biosimilar Sales and Growth Rate (2014-2019)
7 Asia-Pacific Interferon Alpha-2a Biosimilar by Country
7.1 Asia-Pacific Interferon Alpha-2a Biosimilar Sales, Revenue and Market Share by Country
7.1.1 Asia-Pacific Interferon Alpha-2a Biosimilar Sales and Market Share by Country (2014-2019)
7.1.2 Asia-Pacific Interferon Alpha-2a Biosimilar Revenue and Market Share by Country (2014-2019)
7.2 China Interferon Alpha-2a Biosimilar Sales and Growth Rate (2014-2019)
7.3 Japan Interferon Alpha-2a Biosimilar Sales and Growth Rate (2014-2019)
7.4 Korea Interferon Alpha-2a Biosimilar Sales and Growth Rate (2014-2019)
7.5 India Interferon Alpha-2a Biosimilar Sales and Growth Rate (2014-2019)
7.6 Southeast Asia Interferon Alpha-2a Biosimilar Sales and Growth Rate (2014-2019)
8 South America Interferon Alpha-2a Biosimilar by Country
8.1 South America Interferon Alpha-2a Biosimilar Sales, Revenue and Market Share by Country
8.1.1 South America Interferon Alpha-2a Biosimilar Sales and Market Share by Country (2014-2019)
8.1.2 South America Interferon Alpha-2a Biosimilar Revenue and Market Share by Country (2014-2019)
8.2 Brazil Interferon Alpha-2a Biosimilar Sales and Growth Rate (2014-2019)
8.3 Argentina Interferon Alpha-2a Biosimilar Sales and Growth Rate (2014-2019)
8.4 Colombia Interferon Alpha-2a Biosimilar Sales and Growth Rate (2014-2019)
9 Middle East and Africa Interferon Alpha-2a Biosimilar by Countries
9.1 Middle East and Africa Interferon Alpha-2a Biosimilar Sales, Revenue and Market Share by Country
9.1.1 Middle East and Africa Interferon Alpha-2a Biosimilar Sales and Market Share by Country (2014-2019)
9.1.2 Middle East and Africa Interferon Alpha-2a Biosimilar Revenue and Market Share by Country (2014-2019)
9.2 Saudi Arabia Interferon Alpha-2a Biosimilar Sales and Growth Rate (2014-2019)
9.3 Turkey Interferon Alpha-2a Biosimilar Sales and Growth Rate (2014-2019)
9.4 Egypt Interferon Alpha-2a Biosimilar Sales and Growth Rate (2014-2019)
9.5 Nigeria Interferon Alpha-2a Biosimilar Sales and Growth Rate (2014-2019)
9.6 South Africa Interferon Alpha-2a Biosimilar Sales and Growth Rate (2014-2019)
10 Global Interferon Alpha-2a Biosimilar Market Segment by Type
10.1 Global Interferon Alpha-2a Biosimilar Sales, Revenue and Market Share by Type (2014-2019)
10.1.1 Global Interferon Alpha-2a Biosimilar Sales and Market Share by Type (2014-2019)
10.1.2 Global Interferon Alpha-2a Biosimilar Revenue and Market Share by Type (2014-2019)
10.2 Long-lasting Type Sales Growth and Price
10.2.1 Global Long-lasting Type Sales Growth (2014-2019)
10.2.2 Global Long-lasting Type Price (2014-2019)
10.3 Ordinary Type Sales Growth and Price
10.3.1 Global Ordinary Type Sales Growth (2014-2019)
10.3.2 Global Ordinary Type Price (2014-2019)
11 Global Interferon Alpha-2a Biosimilar Market Segment by Application
11.1 Global Interferon Alpha-2a Biosimilar Sales Market Share by Application (2014-2019)
11.2 Hepatitis C Sales Growth (2014-2019)
11.3 Hepatitis B Sales Growth (2014-2019)
11.4 Other Sales Growth (2014-2019)
12 Interferon Alpha-2a Biosimilar Market Forecast (2019-2024)
12.1 Global Interferon Alpha-2a Biosimilar Sales, Revenue and Growth Rate (2019-2024)
12.2 Interferon Alpha-2a Biosimilar Market Forecast by Regions (2019-2024)
12.2.1 North America Interferon Alpha-2a Biosimilar Market Forecast (2019-2024)
12.2.2 Europe Interferon Alpha-2a Biosimilar Market Forecast (2019-2024)
12.2.3 Asia-Pacific Interferon Alpha-2a Biosimilar Market Forecast (2019-2024)
12.2.4 South America Interferon Alpha-2a Biosimilar Market Forecast (2019-2024)
12.2.5 Middle East and Africa Interferon Alpha-2a Biosimilar Market Forecast (2019-2024)
12.3 Interferon Alpha-2a Biosimilar Market Forecast by Type (2019-2024)
12.3.1 Global Interferon Alpha-2a Biosimilar Sales Forecast by Type (2019-2024)
12.3.2 Global Interferon Alpha-2a Biosimilar Market Share Forecast by Type (2019-2024)
12.4 Interferon Alpha-2a Biosimilar Market Forecast by Application (2019-2024)
12.4.1 Global Interferon Alpha-2a Biosimilar Sales Forecast by Application (2019-2024)
12.4.2 Global Interferon Alpha-2a Biosimilar Market Share Forecast by Application (2019-2024)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.1.3 Marketing Channel Future Trend
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
List of Tables and Figures
Figure Interferon Alpha-2a Biosimilar Picture
Table Product Specifications of Interferon Alpha-2a Biosimilar
Figure Global Sales Market Share of Interferon Alpha-2a Biosimi
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
